Navigation Links
13D Amendment Filed for RepliGen Corporation
Date:6/23/2011

CHICAGO, June 23, 2011 /PRNewswire-FirstCall/ -- Mr. Ronald L. Chez, a private investor, filed an amended 13D for RepliGen Corporation (Nasdaq: RGEN) with the SEC.

RepliGen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.  RepliGen has a core competency in the development and manufacturing of biologics products, which serve as the basis for the bioprocessing business. RepliGen has out-licensed certain biologics intellectual property, which provide an ongoing source of revenue. RepliGen's corporate headquarters are located in Waltham, Massachusetts.

Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and a private investor.

Inquiry Contact:
Barry Fischer
(312) 580-2233


'/>"/>
SOURCE Ronald L. Chez
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
2. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
3. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
4. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
5. Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
6. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments
7. Mr. Ronald L. Chez Filed Amended 13D for RepliGen Corporation
8. Recalled DePuy ASR Hip Implant Lawsuits Filed By John David Hart
9. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
10. Recalled DePuy Hip Implant Lawsuits Filed in Fort Worth, Texas
11. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):